http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 11 Mar 2026 09:23:52 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%2494+at+TD+Cowen/26143762.html TD Cowen analyst Yaron Werber lowered the price target on BioNTech (NASDAQ: BNTX) to $94.00 (from $116.00) while maintaining a Hold rating. http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%2494+at+TD+Cowen/26143762.html Wed, 11 Mar 2026 09:23:52 -0400 BNTX http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24128+at+BMO+Capital/26143726.html <p>BMO Capital analyst Evan David Seigerman lowered the price target on BioNTech (NASDAQ: BNTX) to $128.00 (from $143.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Timing Is Everything? CEO/CMO Departure Plans Cause Confusion; Where do we begin? Underwhelming 2026 COVID guide and confusing CEO/CMO departure messaging inject uncertainty ahead of a major year for data. The most notable update from the print was the announcement that co-founders CEO Uğur Şahin and CMO Özlem Türeci will leave to establish a next-gen mRNA technology company. Uncertainty associated with new leadership in light of a vast mid-to-late stage pipeline and accelerating COVID-19 revenue http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24128+at+BMO+Capital/26143726.html Wed, 11 Mar 2026 09:15:56 -0400 BNTX http://www.streetinsider.com/Analyst+Comments/BioNTech+%28BNTX%29+PT+Lowered+to+%24128+at+BMO+Capital/26143726.html <p>BMO Capital analyst Evan David Seigerman lowered the price target on BioNTech (NASDAQ: BNTX) to $128.00 (from $143.00) while maintaining an Outperform rating.</p><p>The analyst commented: "Timing Is Everything? CEO/CMO Departure Plans Cause Confusion; Where do we begin? Underwhelming 2026 COVID guide and confusing CEO/CMO departure messaging inject uncertainty ahead of a major year for data. The most notable update from the print was the announcement that co-founders CEO Uğur Şahin and CMO Özlem Türeci will leave to establish a next-gen mRNA technology company. Uncertainty associated with new leadership in light of a vast mid-to-late stage pipeline and accelerating COVID-19 revenue http://www.streetinsider.com/Analyst+Comments/BioNTech+%28BNTX%29+PT+Lowered+to+%24128+at+BMO+Capital/26143726.html Wed, 11 Mar 2026 09:15:56 -0400 BNTX http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioNTech+SE++++++++++++++++++++++++++++Filed+by%3A+Poetting+Sierk/26142935.html si-local-file:///var/storage/secattach/20260311/26142935.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioNTech+SE++++++++++++++++++++++++++++Filed+by%3A+Poetting+Sierk/26142935.html Wed, 11 Mar 2026 08:03:00 -0400 0A3M BNTX O.07073414 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioNTech+SE++++++++++++++++++++++++++++Filed+by%3A+Poetting+Sierk/26142935.html si-local-file:///var/storage/secattach/20260311/26142935.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioNTech+SE++++++++++++++++++++++++++++Filed+by%3A+Poetting+Sierk/26142935.html Wed, 11 Mar 2026 08:03:00 -0400 0A3M BNTX O.07073414 http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioNTech+SE++++++++++++++++++++++++++++Filed+by%3A+Poetting+Sierk/26142935.html si-local-file:///var/storage/secattach/20260311/26142935.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++BioNTech+SE++++++++++++++++++++++++++++Filed+by%3A+Poetting+Sierk/26142935.html Wed, 11 Mar 2026 08:03:00 -0400 0A3M BNTX O.07073414 http://www.streetinsider.com/Reuters/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html <p>March 11 (Reuters) - A key ‌U.S. federal ​vaccine ​advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing ‌two people familiar with the matter.</p> <p>Some vaccine advisers under ⁠Health and Human Services Secretary Robert F. Kennedy Jr had been seeking ‌to potentially stop recommending ‌mRNA shots, but that plan is no longer moving forward, the report said.</p> http://www.streetinsider.com/Reuters/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html Wed, 11 Mar 2026 06:32:30 -0400 BNTX MRNA PFE http://www.streetinsider.com/Reuters/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html <p>March 11 (Reuters) - A key ‌U.S. federal ​vaccine ​advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing ‌two people familiar with the matter.</p> <p>Some vaccine advisers under ⁠Health and Human Services Secretary Robert F. Kennedy Jr had been seeking ‌to potentially stop recommending ‌mRNA shots, but that plan is no longer moving forward, the report said.</p> http://www.streetinsider.com/Reuters/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html Wed, 11 Mar 2026 06:32:30 -0400 BNTX MRNA PFE http://www.streetinsider.com/Reuters/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html <p>March 11 (Reuters) - A key ‌U.S. federal ​vaccine ​advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing ‌two people familiar with the matter.</p> <p>Some vaccine advisers under ⁠Health and Human Services Secretary Robert F. Kennedy Jr had been seeking ‌to potentially stop recommending ‌mRNA shots, but that plan is no longer moving forward, the report said.</p> http://www.streetinsider.com/Reuters/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html Wed, 11 Mar 2026 06:32:30 -0400 BNTX MRNA PFE http://www.streetinsider.com/General+News/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html <p>March 11 (Reuters) - A key ‌U.S. federal ​vaccine ​advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing ‌two people familiar with the matter.</p> <p>Some vaccine advisers under ⁠Health and Human Services Secretary Robert F. Kennedy Jr had been seeking ‌to potentially stop recommending ‌mRNA shots, but that plan is no longer moving forward, the report said.</p> http://www.streetinsider.com/General+News/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html Wed, 11 Mar 2026 06:32:30 -0400 BNTX MRNA PFE http://www.streetinsider.com/General+News/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html <p>March 11 (Reuters) - A key ‌U.S. federal ​vaccine ​advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing ‌two people familiar with the matter.</p> <p>Some vaccine advisers under ⁠Health and Human Services Secretary Robert F. Kennedy Jr had been seeking ‌to potentially stop recommending ‌mRNA shots, but that plan is no longer moving forward, the report said.</p> http://www.streetinsider.com/General+News/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html Wed, 11 Mar 2026 06:32:30 -0400 BNTX MRNA PFE http://www.streetinsider.com/General+News/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html <p>March 11 (Reuters) - A key ‌U.S. federal ​vaccine ​advisory panel has dropped a push against COVID mRNA vaccines, the Washington Post reported on Wednesday, citing ‌two people familiar with the matter.</p> <p>Some vaccine advisers under ⁠Health and Human Services Secretary Robert F. Kennedy Jr had been seeking ‌to potentially stop recommending ‌mRNA shots, but that plan is no longer moving forward, the report said.</p> http://www.streetinsider.com/General+News/US+vaccine+advisers+drop+plan+to+question+mRNA+COVID+shots%2C+WaPo+reports/26142350.html Wed, 11 Mar 2026 06:32:30 -0400 BNTX MRNA PFE http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24130+at+Citi/26141818.html Citi analyst Geoff Meacham lowered the price target on BioNTech (NASDAQ: BNTX) to $130.00 (from $145.00) while maintaining a Buy rating. http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24130+at+Citi/26141818.html Wed, 11 Mar 2026 05:00:34 -0400 BNTX http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Reiterates+Perform+Rating+on+BioNTech+%28BNTX%29+following+management+changes/26140628.html <p>Oppenheimer analyst Hartaj Singh reiterated a Perform rating on BioNTech (NASDAQ: BNTX)</p><p>The analyst commented, "BNTX's 4Q financial results and pipeline updates were overshadowed by the announcement that co-founders Uger Sahin and Özlem Türeci are leaving the company to form a new independent company focused on next-generation mRNA innovations, sending the shares down as much as 20% on 3/10 (vs. NBI: +0.3%). While we had suspected potential strategic changes, including spinning the mRNA portfolio, this level of leadership transition came as a total surprise, especially considering that BNTX is entering a transitional period with multiple late-stage programs maturing. Despite the growing http://www.streetinsider.com/Analyst+Comments/Oppenheimer+Reiterates+Perform+Rating+on+BioNTech+%28BNTX%29+following+management+changes/26140628.html Tue, 10 Mar 2026 17:14:36 -0400 BNTX http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24167+at+Clear+Street%3A+%22absurd+to+be+trading+near+cash%22/26139299.html <p>Clear Street analyst Bill Maughan lowered the price target on BioNTech (NASDAQ: BNTX) to $167.00 (from $181.00) while maintaining a Buy rating.</p><p>The analyst commented, "On today’s move, we believe it is absurd for shares of BNTX to be trading near cash. For context, just last year BMS (BMY: NYSE, NC) paid $3.5B (+≤$7.6B milestones) for 50% of pumitamig, which remains an intact opportunity with multiple data readouts this year on top of late stage readouts from gotistobart, and an advancing pipeline of ADCs. Meanwhile, guidance implies ~$1B cash burn (Revenue-R&D-SG&A) from operating in FY26E, which is reasonable for the size http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24167+at+Clear+Street%3A+%22absurd+to+be+trading+near+cash%22/26139299.html Tue, 10 Mar 2026 16:05:34 -0400 BNTX http://www.streetinsider.com/Analyst+Comments/BioNTech+%28BNTX%29+PT+Lowered+to+%24167+at+Clear+Street%3A+%22absurd+to+be+trading+near+cash%22/26139299.html <p>Clear Street analyst Bill Maughan lowered the price target on BioNTech (NASDAQ: BNTX) to $167.00 (from $181.00) while maintaining a Buy rating.</p><p>The analyst commented, "On today’s move, we believe it is absurd for shares of BNTX to be trading near cash. For context, just last year BMS (BMY: NYSE, NC) paid $3.5B (+≤$7.6B milestones) for 50% of pumitamig, which remains an intact opportunity with multiple data readouts this year on top of late stage readouts from gotistobart, and an advancing pipeline of ADCs. Meanwhile, guidance implies ~$1B cash burn (Revenue-R&D-SG&A) from operating in FY26E, which is reasonable for the size http://www.streetinsider.com/Analyst+Comments/BioNTech+%28BNTX%29+PT+Lowered+to+%24167+at+Clear+Street%3A+%22absurd+to+be+trading+near+cash%22/26139299.html Tue, 10 Mar 2026 16:05:34 -0400 BNTX http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24138+at+Jefferies/26138993.html <p>Jefferies analyst Akash Tewari lowered the price target on BioNTech (NASDAQ: BNTX) to $138.00 (from $151.00) while maintaining a Buy rating.</p><p>The analyst commented, "BNTX Q4 revs beat cons (€907M vs €759M), but declined ~24% YoY. FY26 rev guide of €2.15Bn at midpoint implies 7% YoY decline (vs ~€2.3Bn FY'25 rev, excl. ~€0.6Bn payment from BMY deal). CEO & CMO transition was surprising - that said, we think stock is cheap (trading ~cash) & co has 15+ Ph3 readouts that can enter market next few yrs. If BNTX brings in right successor that can improve communication & focus on clinical/commercial execution, http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24138+at+Jefferies/26138993.html Tue, 10 Mar 2026 15:41:37 -0400 BNTX http://www.streetinsider.com/Analyst+Comments/BioNTech+%28BNTX%29+PT+Lowered+to+%24138+at+Jefferies/26138993.html <p>Jefferies analyst Akash Tewari lowered the price target on BioNTech (NASDAQ: BNTX) to $138.00 (from $151.00) while maintaining a Buy rating.</p><p>The analyst commented, "BNTX Q4 revs beat cons (€907M vs €759M), but declined ~24% YoY. FY26 rev guide of €2.15Bn at midpoint implies 7% YoY decline (vs ~€2.3Bn FY'25 rev, excl. ~€0.6Bn payment from BMY deal). CEO & CMO transition was surprising - that said, we think stock is cheap (trading ~cash) & co has 15+ Ph3 readouts that can enter market next few yrs. If BNTX brings in right successor that can improve communication & focus on clinical/commercial execution, http://www.streetinsider.com/Analyst+Comments/BioNTech+%28BNTX%29+PT+Lowered+to+%24138+at+Jefferies/26138993.html Tue, 10 Mar 2026 15:41:37 -0400 BNTX http://www.streetinsider.com/Options/BioNTech+SE+%28BNTX%29+June+80+and+September+55+puts+active+as+share+price+down+17.7%25/26138833.html <p>BioNTech SE (NASDAQ: BNTX) 30-day option implied volatility is at 47; compared to its 52-week range of 33 to 108. Call put ratio 1.8 calls to 1 put with a focus on June 80 and September 55 puts as share price down 17.7%.</p> http://www.streetinsider.com/Options/BioNTech+SE+%28BNTX%29+June+80+and+September+55+puts+active+as+share+price+down+17.7%25/26138833.html Tue, 10 Mar 2026 15:14:53 -0400 BNTX http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+BioNTech+%28BNTX%29+following+earnings%2C+management+changes/26138599.html <p>Truist Securities analyst Asthika Goonewardene reiterated a Buy rating and $155.00 price target on BioNTech (NASDAQ: BNTX)</p><p>The analyst commented, "BNTX’s FY26 revenue guidance of €2.0B–€2.3B was in line with our estimate of €2.2B, but considerably below consensus' €2.7B, driven by the company’s expectation for lower COVID-19 vaccine revenues in the US and Europe versus 2025. In addition, BNTX announced a management transition by the end of 2026, with the current CEO & CMO spinning out into a mRNA-focused biotech, and an executive search underway to find a new leader to keep BNTX on track and focused on Pumitamig and ADC http://www.streetinsider.com/Analyst+Comments/Truist+Securities+Reiterates+Buy+Rating+on+BioNTech+%28BNTX%29+following+earnings%2C+management+changes/26138599.html Tue, 10 Mar 2026 14:28:51 -0400 BNTX http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24128+at+BofA+Securities/26138006.html <p>BofA Securities analyst Tazeen Ahmad lowered the price target on BioNTech (NASDAQ: BNTX) to $128.00 (from $134.00) while maintaining a Buy rating.</p><p>The analyst comments "BioNTech (BNTX) announced that co-founders Ugur Sahin, CEO and Özlem Türeci, CMO will be transitioning to establish a new independent company focusing on mRNA innovation. The company highlighted the current pipeline and COVID franchise will not be impacted by the transition. BNTX commented that the search for successors focusing on candidates with extensive experience in late-stage clinical development and commercialization is underway, and the transition is expected by YE. We think the transition makes sense as http://www.streetinsider.com/Analyst+PT+Change/BioNTech+%28BNTX%29+PT+Lowered+to+%24128+at+BofA+Securities/26138006.html Tue, 10 Mar 2026 12:29:12 -0400 BNTX http://www.streetinsider.com/Analyst+Comments/BioNTech+%28BNTX%29+PT+Lowered+to+%24128+at+BofA+Securities/26138006.html <p>BofA Securities analyst Tazeen Ahmad lowered the price target on BioNTech (NASDAQ: BNTX) to $128.00 (from $134.00) while maintaining a Buy rating.</p><p>The analyst comments "BioNTech (BNTX) announced that co-founders Ugur Sahin, CEO and Özlem Türeci, CMO will be transitioning to establish a new independent company focusing on mRNA innovation. The company highlighted the current pipeline and COVID franchise will not be impacted by the transition. BNTX commented that the search for successors focusing on candidates with extensive experience in late-stage clinical development and commercialization is underway, and the transition is expected by YE. We think the transition makes sense as http://www.streetinsider.com/Analyst+Comments/BioNTech+%28BNTX%29+PT+Lowered+to+%24128+at+BofA+Securities/26138006.html Tue, 10 Mar 2026 12:29:12 -0400 BNTX http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Reiterates+Overweight+Rating+on+BioNTech+%28BNTX%29%3A+%22timing+of+announcement+likely+driving+weakness+in+stock%22/26137899.html <p>Morgan Stanley analyst Terence Flynn reiterated an Overweight rating and $134.00 price target on BioNTech (NASDAQ: BNTX)</p><p>The analyst commented, "BNTX announced a leadership transition by YE26 (LINK). BNTX's current CEO and CMO (and co-founders) will leave to head a NewCo, focused on next-gen mRNA innovations. BNTX plans to contribute related rights and mRNA technologies to the new company on an arm’s length basis in exchange for a minority stake and other forms of consideration such as milestones and royalties. Signing of binding agreements is expected by the end of 1H26. Per the conference call the company noted there are no http://www.streetinsider.com/Analyst+Comments/Morgan+Stanley+Reiterates+Overweight+Rating+on+BioNTech+%28BNTX%29%3A+%22timing+of+announcement+likely+driving+weakness+in+stock%22/26137899.html Tue, 10 Mar 2026 12:06:20 -0400 BNTX http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++BioNTech+SE+++++++++++++++For%3A+Dec+31/26135039.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260310/APVZB22CZ22FD2Z2222G22ZKQBCBZZ229E82">http://archive.fast-edgar.com/20260310/APVZB22CZ22FD2Z2222G22ZKQBCBZZ229E82</a></p> <p> Filed on: March 10, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++BioNTech+SE+++++++++++++++For%3A+Dec+31/26135039.html Tue, 10 Mar 2026 06:56:00 -0400 0A3M BNTX O.07073414 http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++BioNTech+SE+++++++++++++++For%3A+Dec+31/26135039.html <p><a target="_blank" href="http://archive.fast-edgar.com/20260310/APVZB22CZ22FD2Z2222G22ZKQBCBZZ229E82">http://archive.fast-edgar.com/20260310/APVZB22CZ22FD2Z2222G22ZKQBCBZZ229E82</a></p> <p> Filed on: March 10, 2026 </p> http://www.streetinsider.com/SEC+Filings/Form++20-F+++++++BioNTech+SE+++++++++++++++For%3A+Dec+31/26135039.html Tue, 10 Mar 2026 06:56:00 -0400 0A3M BNTX O.07073414